Drug therapy in autism: A present and future perspective

Pharmacological Reports

Volumn 64, Issue 6, 2012, Pages 1291-1304

  Kumar, Baldeep ^a   Prakash, Ajay ^a   Sewal, Rakesh K ^a   Medhi, Bikash ^a   Modi, Manish ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

ASD; Autism; Behavior; Clinical studies; Drugs

Indexed keywords

AMANTADINE; ARIPIPRAZOLE; ASCORBIC ACID; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINESTERASE INHIBITOR; CLOMIPRAMINE; CLONIDINE; CLOZAPINE; CYANOCOBALAMIN; DESIPRAMINE; DOCOSAHEXAENOIC ACID; FLUOXETINE; FLUVOXAMINE; GLUTAMATE RECEPTOR ANTAGONIST; GUANFACINE; IMIPRAMINE; LAMOTRIGINE; MELATONIN; METHYLPHENIDATE; NALTREXONE; NORTRIPTYLINE; OMEGA 3 FATTY ACID; PLACEBO; PROBIOTIC AGENT; RISPERIDONE; RIVASTIGMINE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE; ZIPRASIDONE;

AGGRESSION; ALTERNATIVE MEDICINE; ANEMIA; ANOREXIA; ANTICONVULSANT ACTIVITY; ANTIOXIDANT ACTIVITY; ANXIETY DISORDER; APPETITE; AUDIOMETRY; AUTISM; AUTOMUTILATION; BEDTIME DOSAGE; BEHAVIOR DISORDER; BEHAVIOR THERAPY; BLOOD CELL COUNT; BLURRED VISION; COMPULSION; DEPRESSION; DETOXIFICATION; DIARRHEA; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISINHIBITION; DIZZINESS; DROWSINESS; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DSM-IV-TR; ENVIRONMENTAL STRESS; EXTRAPYRAMIDAL SYMPTOM; EYE EXAMINATION; FATIGUE; FATTY ACID BLOOD LEVEL; FRAGILE X SYNDROME; GENE MUTATION; HEARING IMPAIRMENT; HEAVY METAL POISONING; HEMATOLOGIC DISEASE; HUMAN; HYPERACTIVITY; HYPERBARIC OXYGEN; HYPOMANIA; IMMUNE DYSREGULATION; IMPULSE CONTROL DISORDER; INCIDENCE; INSOMNIA; INTERPERSONAL COMMUNICATION; IRRITABILITY; MENTAL INSTABILITY; MOOD DISORDER; NAUSEA; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PATIENT EDUCATION; PREVALENCE; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SOCIAL INTERACTION; SPEECH THERAPY; STEREOTYPY; TIC; TUBEROUS SCLEROSIS; UNSPECIFIED SIDE EFFECT; VISUAL IMPAIRMENT; WEIGHT GAIN;

EID: 84873712460     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(12)70927-1     Document Type: Review

References (133)

1. Abrahams BS, Geschwind DH: Advances in autism genetics: on the threshold of a new neurobiology. Nat RevGenet, 2008, 9, 341-355. (Pubitemid 351556064)
2. Adams JB, Baral M, Geis E, Mitchell J, Ingram J,Hensley A, Zappia I et al.: The severity of autism is associated with toxic metal body burden and red blood cellglutathione levels. J Toxicol, 2009, 2009, 532-640.
3. Aman MG: Management of hyperactivity and otheracting-out problems in patients with autism spectrumdisorder. Semin Pediatr Neurol, 2004, 11, 225-228.
4. American Psychiatric Association: Diagnostic and statistical manual of mental disorders (DSM IV), 4th edn.,APA, Washington, DC, 1994.
5. American Psychiatric Association: Diagnostic and statistical manual of mental disorders (DSM-IV-TR), 4th edn.,Text revision, APA, Washington, DC, 2000.
6. Anagnostou E, Esposito K, Soorya L, Chaplin W,Wasserman S, Hollander E: Divalproex versus placebofor the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder. J Clin Psychopharmacol, 2006, 26, 444-446. (Pubitemid 44187659)
7. Angley M, Semple S, Hewton C, Paterson F, McKinnonR: Children and autism - Part 2 - Management with complementary medicines and dietary interventions.Aust Fam Physician, 2007, 36, 827-830.
8. 2 in autistic spectrum disorders. Prostaglandins LeukotEssent Fatty Acids, 2004, 71, 201-204.
9. Bent S, Bertoglio K, Hendren RL: Omega-3 fatty acidsfor autistic spectrum disorder: a systematic review.J Autism Dev Disord, 2009, 39, 1145-1154.
10. Bertone A, Hanck J, Kogan C, Chaudhuri A, Cornish K:Associating neural alterations and genotype in autismand fragile X syndrome: incorporating perceptual phenotypes in causal modeling. J Autism Dev Disord, 2010,40, 1541-1548.
11. Bertrand J, Mars A, Boyle C, Bove F, Yeargin-AllsoppM, Decoufle P: Prevalence of autism in a United Statespopulation: the Brick Township, New Jersey, investigation. Pediatrics, 2001, 108, 1155-1161. (Pubitemid 33021192)
12. Bishop DVM: Autism, Asperger's syndrome and semantic-pragmatic disorder: where are the boundaries?Br J Disord Commun, 1989, 24, 107-121.
13. Boellner SW, Pennick M, Fiske K, Lyne A, Shojaei A:Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. Pharmacotherapy, 2007,27, 1253-1262. (Pubitemid 47339123)
14. Borras C, Sastre J, Garcia-Sala D, Lloret A, Pallardo FV,Vina J: Mitochondria from females exhibit higher antioxidant gene expression and lower oxidative damagethan males. Free Radic Biol Med, 2003, 34, 546-552. (Pubitemid 36254828)
15. Bouvard MP, Leboyer M, Launay JM, Recasens C, Plumet MH, Waller-Perotte D, Tabuteau F et al.: Low-dosenaltrexone effects on plasma chemistries and clinicalsymptoms in autism: a double-blind, placebo-controlledstudy. Psychiatry Res, 1995, 58, 191-201.
16. Bradstreet JJ, Smith S, Baral M, Rossignol DA:Biomarker-guided interventions of clinically relevantconditions associated with autism spectrum disordersand attention deficit hyperactivity disorder. Altern MedRev, 2010, 15, 15-32.
17. Campbell M, Fish B, Shapiro T, Floyd A: Imipraminein preschool autistic and schizophrenic children.J Autism Child Schizophr, 1971, 1, 267-282.
18. Campbell M, Overall JE, Small AM, Sokol MS, SpencerEK, Adams P, Foltz RL et al.: Naltrexone in autistic children: an acute open dose range tolerance trial. J AmAcad Child Adolesc Psychiatry, 1989, 28, 200-206. (Pubitemid 19086187)
19. Carminati GG, Deriaz N, Bertschy G: Low-dose venlafaxine in three adolescents and young adults with autisticdisorder improves self-injurious behaviour and attentiondeficit/hyperactivity disorders (ADHD)-like symptoms.Prog Neuropsychopharmacol Biol Psychiatry, 2006, 30,312-315. (Pubitemid 43288074)
20. Centers for Disease Control and Prevention (CDC):Mental health in the United States: parental report ofdiagnosed autism in children aged 4-17 years - United States, 2003-2004. MMWR Morb Mortal Wkly Rep, 2006, 55, 481-486.
21. Chao HT, Chen H, Samaco RC, Xue M, Chahrour M,Yoo J, Neul JL et al.: Dysfunction in GABA signallingmediates autism-like stereotypies and Rett syndromephenotypes. Nature, 2010, 468, 263-269.
22. Charman T, Baird G: Practitioner review: Diagnosis ofautism spectrum disorder in 2- and 3- year-old children.J Child Psychol Psychiatry, 2002, 43, 289-305. (Pubitemid 36939219)
23. Charman T, Loucas T, Pickles A, Simonoff E, ChandlerS, Meldrum D, Baird G: Autistic symptomatology andlanguage ability in autism spectrum disorder and specificlanguage impairment. J Child Psychol Psychiatry, 2008,49, 1184-1192.
24. Chauhan A, Chauhan V: Oxidative stress in autism.Pathophysiology, 2006, 13, 171-181.
25. Chauhan A, Chauhan V, Brown WT, Cohen I: Oxidativestress in autism: increased lipid peroxidation and reducedserum levels of ceruloplasmin and transferrin - the antioxidant proteins. Life Sci, 2004, 75, 2539-2549. (Pubitemid 39195260)
26. Chen NC, Bedair HS,McKay B, BowersMB,Mazure C:Clozapine in the treatment of aggression in an adolescentwith autistic disorder. J Clin Psychiatry, 2001, 62, 479-480 (Pubitemid 32717889)
27. Chez MG, Aimonovitch M, Buchanan T, Mrazek S,Tremb RJ: Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigminetartate. J Child Neurol, 2004, 19, 165-169. (Pubitemid 38559707)
28. Chez MG, Burton Q, Dowling T, Chang M, Khanna P,Kramer C: Memantine as adjunctive therapy in childrendiagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol, 2007, 22, 574-579. (Pubitemid 46951501)
29. Choudhury PR, Lahiri S, Rajamma U: Glutamate mediatedsignaling in the pathophysiology of autism spectrumdisorders. Pharmacol Biochem Behav, 2012, 100, 841-849.
30. Clifford S, Dissanayake C, Bui QM, Huggins R, TaylorAK, Loesch DZ: Autism spectrum phenotype in malesand females with fragile X full mutation and premutation. J Autism Dev Disord, 2007, 37, 738-747. (Pubitemid 46571729)
31. Clinical Practice Guideline. Report of the guideline recommendations. Autism / pervasive developmental disorders. Assessment and intervention for young children(age 0-3 years). New York: New York State Department of Health, Early Intervention Program, 1999. Availableonline at: http://www.health.state. ny.us/community/infants-children/early-intervention/autism/[Last accessed23 December 2010].
32. Cody H, Pelphrey K, Piven J: Structural and functionalmagnetic resonance imaging of autism. Int J Dev Neurosci, 2002, 20, 421-438.
33. Cohen IL, Sudhalter V, Pfadt A, Jenkins EC, Brown WT,Vietze PM: Why are autism and the fragile-X syndromeassociated? Conceptual and methodological issues. AmJ Hum Genet, 1991, 48, 195-202. (Pubitemid 21891582)
34. Committee on Educational Interventions for Childrenwith Autism, National Research Council: Educating children with autism, National Academy Press, Washington,DC, 2001.
35. Dawson G, Webb S, Schellenberg GD, Dager S,Friedman S, Aylward E, Richards T: Defining thebroader phenotype of autism: Genetic, brain and behavioral perspectives. Dev Psychopathol, 2002, 14,581-611. (Pubitemid 351690090)
36. DeLong GR, Ritch CR, Burch S: Fluoxetine response inchildren with autistic spectrum disorders: correlationwith familial major affective disorder and intellectualachievement. Dev Med Child Neurol, 2002, 44, 652-659. (Pubitemid 35230025)
37. D'Hulst C, Heulens I, Brouwer JR, Willemsen R, De Geest N, Reeve SP, De Deyn PP: Expression ofthe GABAergic system in animal models for fragile Xsyndrome and fragile X associated tremor/ataxia syndrome (FXTAS). Brain Res, 2009, 1253, 176-183.
38. Di Martino A, Melis G, Cianchetti C, Zuddas A:Methylphenidate for pervasive developmental disorders:safety and efficacy of acute single dose test and ongoingtherapy: an open-pilot study. J Child Adolesc Psychopharmacol, 2004, 14, 207-218 (Pubitemid 38988787)
39. Dolske MC, Spollen J, McKay S, Lancashire E, TolbertL: A preliminary trial of ascorbic acid as supplementaltherapy for autism. Prog Neuropsychopharmacol BiolPsychiatry, 1993, 17, 765-774. (Pubitemid 23280951)
40. Droge W, Breitkreutz R: Glutathione and immune function. Proc Nutr Soc, 2000, 59, 595-600. (Pubitemid 32002990)
41. Ehninger D, Silva AJ: Rapamycin for treating tuberoussclerosis and autism spectrum disorders. Trends MolMed, 2011, 17, 78-87.
42. Elchaar GM, Maisch NM, Augusto LM, Wehring HJ:Efficacy and safety of naltrexone use in pediatric patientswith autistic disorder. Ann Pharmacother, 2006, 40,1086-1095. (Pubitemid 43886966)
43. El-Hazmi MA: Autism and mental retardation: the genetic relationship and contribution. East Mediterr HealthJ, 2001, 7, 536-543. (Pubitemid 33758977)
44. Fankhauser MP, Karumanchi VC, German ML, Yates A,Karumanchi SD: A double-blind, placebo-controlledstudy of the efficacy of transdermal clonidine in autism.J Clin Psychiatry, 1992, 53, 77-82
45. Fatemi SH, Realmuto GM, Khan L, Thuras P: Fluoxetinein treatment of adolescent patients with autism: a longitudinalopen trial. J Autism Dev Disord, 1998, 28, 303-307. (Pubitemid 28368957)
46. Fatemi SH, Reutiman TJ, Folsom TD, Rooney RJ, PatelDH, Thuras PD: mRNA and protein levels forGABAAa4, a5, b1 and GABABR1 receptors are alteredin brains from subjects with autism. J Autism Dev Disord, 2010, 40, 743-750.
47. Filipek PA, Accardo PJ, Ashwal S, Baranek GT, CookEH, Dawson G, Gordon B et al.: Practice parameter:Screening and diagnosis of autism: Report of the QualityStandards Subcommittee of the American Academy ofNeurology and the Child Neurology Society. Neurology,2000, 55, 468-479. (Pubitemid 30647241)
48. Findling RL: Pharmacologic treatment of behavioralsymptoms in autism and pervasive developmental disorders. J Clin Psychiatry, 2005, 66, 26-31.
49. Fombonne E: Epidemiology of autistic disorder andother pervasive developmental disorders. J Clin Psychiatry, 2005, 66, 3-8.
50. Freeman MP, Hibbeln JR, Wisner KL, Davis JM,Mischoulon D, Peet M, Keck PE et al.: Omega-3 fattyacids: Evidence basis for treatment and future researchin psychiatry. J Clin Psychiatry, 2006, 67, 1954-1967. (Pubitemid 46048194)
51. Garvey J: Diet in autism and associated disorders. J FamHealth Care, 2002, 12, 34-38.
52. Gobbi G, Pulvirenti L: Long-term treatment with clozapine in an adult with autistic disorder. J Psychiatry Neurosci, 2001, 26, 340-341
53. Gordon CT, State RC, Nelson JE: A double-blind comparison of clomipramine, desipramine, and placebo inthe treatment of autistic disorder. Arch Gen Psychiatry,1993, 50, 441-447. (Pubitemid 23169937)
54. Green VA, Pituch KA, Itchon J, Choi A, OReilly M,Sigafoos J: Internet survey of treatments used by parentsof children with autism. Res Dev Disabil, 2006, 27,70-84. (Pubitemid 41785473)
55. Handen BL, Johnson CR, Lubetsky M: Efficacy ofmethylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J AutismDev Disord, 2000, 30, 245-255
56. Hanson E, Kalish LA, Bunce E, Curtis C, McDaniel S,Ware J, Petry J: Use of complementary and alternativemedicine among children diagnosed with autism spectrum disorder. J Autism Dev Disord, 2007, 37, 628-636. (Pubitemid 46571719)
57. Hardan AY, Handen BL: A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol, 2002, 12,237-241. (Pubitemid 35191350)
58. Herbert MR, Russo JP, Yang S, Roohi J, Blaxill M, Kahler SG, Cremer L, Hatchwell E: Autism and environmental genomics. Neurotoxicology, 2006, 27, 671-684. (Pubitemid 44232987)
59. Herbert MR: Autism: a brain disorder or a disorder that affectsthe brain? Clin Neuropsychiatry, 2005, 2, 354-379.
60. Hollander E, Chaplin W, Soorya L, Wasserman S,Novotny S, Rusoff J, Feirsen N et al.: Divalproex sodiumvs placebo for the treatment of irritability in children andadolescents with autism spectrum disorders. Neuropsychopharmacology, 2010, 35, 990-998.
61. Hollander E, Phillips A, Chaplin W, Zagursky K,Novotny S, Wasserman S, Iyengar R: A placebo controlled crossover trial of liquid fluoxetine on repetitivebehaviors in childhood and adolescent autism. Neuropsychopharmacology, 2005, 30, 582-589. (Pubitemid 40271160)
62. Hollander E, Phillips AT, Yeh CC: Targeted treatmentsfor symptom domains in child and adolescent autism.Lancet, 2003, 362, 732-734. (Pubitemid 37101074)
63. Hollander E, Soorya L, Wasserman S, Esposito K,Chaplin W, Anagnostou E: Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autismspectrum disorder. Int J Neuropsychopharmacol, 2006, 9,209-213. (Pubitemid 43255834)
64. Horvath K, Perman JA: Autism and gastrointestinalsymptoms. Curr Gastroenterol Rep, 2002, 4, 251-258.
65. James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW, Neubrander JA: Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr, 2004, 80,1611-1617. (Pubitemid 41103861)
66. James SJ, Melnyk S, Fuchs G, Reid T, Jernigan S, PavlivO, Hubanks A, Gaylor DW: Efficacy of methylcobalamin and folinic acid treatment on glutathione redoxstatus in children with autism. Am J Clin Nutr, 2009, 89,425-430.
67. James SJ, Melnyk S, Jernigan S, Cleves MA, HalstedCH, Wong DH, Cutler P et al.: Metabolic endophenotypeand related genotypes are associated with oxidativestress in children with autism. Am J Med Genet B Neuropsychiatr Genet, 2006, 141B, 947-956. (Pubitemid 44905454)
68. Jepson B, Johnson J: Changing the Course of Autism:A Scientific Approach for Parents and Physicians, Sentient Publications, Boulder, CO, 2007.
69. Jyonouchi H, Geng L, Ruby A, Zimmerman-Bier B:Dysregulated innate immune responses in young children with autism spectrum disorders: their relationshipto gastrointestinal symptoms and dietary intervention.Neuropsychobiology, 2005, 51, 77-85. (Pubitemid 40522799)
70. Karande S: Autism: A review for family physicians.Indian J Med Sci, 2006, 60, 205-215.
71. Keen D, Ward S: Autistic spectrum disorder: A childpopulation profile. Autism, 2004, 8, 39-48. (Pubitemid 38239621)
72. King BH, Wright DM, Handen BL, Sikich L, Zimmerman AW, McMahon W, Cantwell E: Double-blind,placebo-controlled study of amantadine hydrochloridein the treatment of children with autistic disorder. J AmAcad Child Adolesc Psychiatry, 2001, 40, 658-665. (Pubitemid 32473379)
73. Kogan MD, Blumberg SJ, Schieve LA, Boyle CA, PerrinJM, Ghandour RM, Singh GK et al.: Prevalence ofparent-reported diagnosis of autism spectrum disorderamong children in the US, 2007. Pediatrics, 2009, 124,1395-1403.
74. Kolmen BK, Feldman HM, Handen BL, Janosky JE:Naltrexone in young autistic children: a double-blind,placebo-controlled crossover study. J Am Acad ChildAdolesc Psychiatry, 1995, 34, 223-231.
75. Kołomańska P, Wyszogrodzka E, Rok-Bujko P, Krza̧ścik P, Kostowski W, Zaniewska M, Filip M et al.: Neonatalserotonin (5-HT) depletion does not disrupt prepulse inhibition of the startle response in rats. Pharmacol Rep,2011, 63, 1077-1084.
76. Kurtis LB: Clinical study of the response to nortriptyline onautistic children. Int J Neuropsychiatry, 1966, 2, 298-301.
77. Levy SE, Hyman SL: Complementary and alternativemedicine treatments for children with autism spectrumdisorders. Child Adolesc Psychiatr Clin N Am, 2008, 17,803-820.
78. Martin A, Koenig K, Anderson GM, Scahill L: Lowdose fluvoxamine treatment in children and adolescentswith pervasive developmental disorders: a prospective,open-label study. J Autism Dev Disord, 2003, 33, 77-85. (Pubitemid 36323142)
79. Matson JL, Sipes M, Fodstad JC, Fitzgerald ME: Issuesin the management of challenging behaviours of adultswith autism spectrum disorder. CNS Drugs, 2011, 25,597-606.
80. McCracken JT, McGough J, Shah B, Cronin P, Hong D,Aman MG, Arnold LE et al.: Risperidone in childrenwith autism and serious behavioral problems. N EnglJ Med, 2002, 347, 314-321 (Pubitemid 34815353)
81. McDougle CJ, Brodkin ES, Naylor ST, Carlson DC,Cohen DJ, Price LH: Sertraline in adults with pervasivedevelopmental disorders: a prospective open-label investigation. J Clin Psychopharmacol, 1998, 18, 62-66. (Pubitemid 28045636)
82. McDougle CJ, Erickson CA, Stigler KA, Posey DJ: Neurochemistry in the pathophysiology of autism. J ClinPsychiatr, 2005, 66, 9-18. (Pubitemid 43133209)
83. McDougle CJ, Holmes JP, Carlson DC, Pelton GH,Cohen DJ, Price LH: A double-blind, placebo controlledstudy of risperidone in adults with autistic disorder andother pervasive developmental disorders. Arch Gen Psychiatry, 1998, 55, 633-641. (Pubitemid 28340352)
84. McDougle CJ, Kem DL, Posey DJ: Case series: use ofziprasidone for maladaptive symptoms in youths withautism. J Am Acad Child Adolesc Psychiatry, 2002, 41,921-927. (Pubitemid 38338071)
85. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH: A double-blind, placebo controlledstudy of fluvoxamine in adults with autistic disorder.Arch Gen Psychiatry, 1996, 53, 1001-1008. (Pubitemid 26384669)
86. McEachin JJ, Smith T, Lovaas OI: Long-term outcomefor children with autism who received early intensive behavioraltreatment. Am J Ment Retard, 1993, 97, 359-372. (Pubitemid 23104584)
87. Meguid NA, Atta HM, Gouda AS, Khalil RO: Role ofpolyunsaturated fatty acids in the management of Egyptian children with autism. Clin Biochem, 2008, 41,1044-1048.
88. Ming X, Gordon E, Kang N, Wagner GC: Use of clonidine in children with autism spectrum disorders. BrainDev, 2008, 30, 454-460.
89. Moore ML, Eichner SF, Jones JR: Treating functionalimpairment of autism with selective serotonin reuptakeinhibitors. Ann Pharmacother, 2004, 38, 1515-1519. (Pubitemid 39100208)
90. 123I-iomazenil SPECT study.Brain Dev, 2012, 34, 648-654.
91. Muhle R, Trentacoste SV, Rapin I: The genetics ofautism. Pediatrics, 2004, 113, e472-e486.
92. Newschaffer CJ, Croen LA, Daniels J, Giarelli E, Grether JK, Levy SE, Mandell DS et al.: The epidemiologyof autism spectrum disorders. Annu Rev Public Health,2007, 28, 235-258.
93. Nickel RE. Controversial therapies for young childrenwith developmental disabilities. Infants Young Child,1996, 8, 29-40.
94. Nicolson R, Craven-Thuss B, Smith J: A prospective,open-label trial of galantamine in autistic disorder.J Child Adolesc Psychopharmacol, 2006, 16, 621-629. (Pubitemid 44737215)
95. Niederhofer H, Staffen W, Mair A: Galantamine may beeffective in treating autistic disorder. BMJ, 2002, 325,1422.
96. Ohnishi T, Matsuda H, Hashimoto T, Kunihiro T, NishikawaM,Uema T, SasakiM:Abnormal regional cerebralblood flowin childhood autism. Brain, 2000, 123, 1838-1844. (Pubitemid 30664286)
97. Ospina MB, Krebs Seida J, Clark B, Karkhaneh M,Hartling L, Tjosvold L, Vandermeer B, Smith V: Behavioural and developmental interventions for autism spectrum disorder: a clinical systematic review. PLoS One,2008, 3, e3755.
98. Owens DF, Kriegstein AR: Is there more to GABAthansynaptic inhibition? Nat Rev Neurosci, 2002, 3, 715-727.
99. Owley T, Salt J, Guter S, Grieve A, Walton L, Ayuyao N,Leventhal BL: A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders.J Child Adolesc Psychopharmacol, 2006, 16, 517-524. (Pubitemid 44737207)
100. Owley T, Walton L, Salt J, Guter SJ, Winnega M, Leventhal BL: An open-label trial of escitalopram in pervasivedevelopmental disorders. J Am Acad Child Adolesc Psychiatry, 2005, 44, 343-348. (Pubitemid 40393272)
101. Ozonoff S, Williams BJ, Rauch AM, Opitz JO: Behaviorphenotype of FG syndrome: cognition, personality andbehavior: eleven affected boys. Am J Med Genet, 2000,97, 112-118.
102. Panksepp J, Lensing P: Brief report: a synopsis ofan open-trial of naltrexone treatment of autism with fourchildren. J Autism Dev Disord, 1991, 21, 243-249.
103. Pardo CA, Vargas DL, Zimmerman AW: Immunity, neuroglia and neuroinflammation in autism. Int Rev Psychiatry, 2005, 17, 485-495. (Pubitemid 43086675)
104. Pastore A, Federici G, Bertini E, Piemonte F: Analysisof glutathione: implication in redox and detoxification.Clin Chim Acta, 2003, 333, 19-39. (Pubitemid 36694824)
105. Perry EK, Lee ML, Martin-Ruiz CM, Court JA, VolsenSG, Merrit J, Folly E et al.: Cholinergic activity inautism: abnormalities in the cerebral cortex and basalforebrain. Am J Psychiatry, 2001, 158, 1058-1066. (Pubitemid 32623109)
106. Persico AM, Militerni R, Bravaccio C, Schneider C,Melmed R, Trillo S, Montecchi F et al.: Adenosine deaminase alleles and autistic disorder: case-control andfamily-based association studies. Am J Med Genet,2000, 96, 784-790.
107. Piechal A, Blecharz-Klin K, Wyszogrodzka E,Kołomańska P, Rok-Bujko P, Krza̧ścik P, Kostowski W et al.: Neonatal serotonin (5-HT) depletion does notaffect spatial learning and memory in rats. PharmacolRep, 2012, 64, 266-274.
108. Posey DI, Litwiller M, Koburn A, McDougle CJ: Paroxetine in autism. J Am Acad Child Adolesc Psychiatry,1999, 38, 111-112.
109. Posey DJ, Erickson CA, Stigler KA, McDougle CJ: Theuse of selective serotonin reuptake inhibitors in autismand related disorders. J Child Adolesc Psychopharmacol,2006, 16, 181-186.
110. Posey DJ, Puntney JI, Sasher TM, Kem DL, McDougleCJ: Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol, 2004, 14, 233-241 (Pubitemid 38988789)
111. Purcell AE, Jeon OH, Zimmerman AW, Blue ME,Pevsner J: Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology,2001, 57, 1618-1628. (Pubitemid 33055480)
112. Quincozes-Santos A, Bobermin LD, Kleinkauf-Rocha J,Souza DO, Riesgo R, Gonçalves CA, Gottfried C: Atypical neuroleptic risperidone modulates glial functions inC6 astroglial cells. Prog Neuropsychopharmacol BiolPsychiatry, 2009, 33, 11-15.
113. Rossignol DA: Hyperbaric oxygen therapy might improve certain pathophysiological findings in autism.Med Hypotheses, 2007, 68, 1208-1227.
114. Rossignol DA, Bradstreet JJ: Evidence of mitochondrialdysfunction in autism and implications for treatment.Am J Biochem Biotech, 2008, 4, 208-217. (Pubitemid 351573654)
115. Rossignol DA, Rossignol LW: Hyperbaric oxygen therapy may improve symptoms in autistic children. Med Hypotheses, 2006, 67, 216-228.
116. Rugino TA, Samsock TC: Levetiracetam in autistic children: an open-label study. J Dev Behav Pediatr, 2002, 23,225-230. (Pubitemid 34947180)
117. Sanchez LE, Campbell M, Small AM, Cueva JE,Armenteros JL, Adams PB: A pilot study of clomipramine in young autistic children. J Am Acad ChildAdolesc Psychiatry, 1996, 35, 537-544 (Pubitemid 126418618)
118. Srinivasan P: A review of dietary interventions in autism.Ann Clin Psychiatry, 2009, 21, 237-247.
119. Starkstein SE, Vazquez S, Vrancic D, Nanclares V,Manes F, Piven J, Plebst C: SPECT findings in mentallyretarded autistic individuals. J Neuropsychiatry ClinNeurosci, 2000, 12, 370-375. (Pubitemid 30663736)
120. Stone WL, Lee EB, Ashford L, Brissie J, Hepburn SL,Coonrod EE, Weiss BH: Can autism be diagnosed accurately in children under 3 years? J Child Psychol Psychiatr, 1999, 40, 219-226. (Pubitemid 29078366)
121. Summers JA, Allison DB, Lynch PS, Sandler L: Behaviour problems in Angelman syndrome. J Intellect DisabilRes, 1995, 39, 97-106.
122. Tierney E, Nwokoro NA, Porter FD, Freund LS, Ghuman JK, Kelley RI: Behavior phenotype in theRSH/Smith-Lemli-Opitz syndrome. Am J Med Genet,2001, 98, 191-200.
123. Uvebrant P, Bauziene R: Intractable epilepsy in children:the efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics, 1994, 25,284-289.
124. Valicenti-McDermott M, McVicar K, Rapin I, WershilBK, Cohen H, Shinnar S: Frequency of gastrointestinalsymptoms in children with autistic spectrum disordersand association with family history of autoimmune disease. J Dev Behav Pediatr, 2006, 27, S128-S136. (Pubitemid 44620294)
125. Vargas DL, Nascimbene C, Krishnan C, ZimmermanAW, Pardo CA: Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol,2005, 57, 67-81. (Pubitemid 40053317)
126. Volkmar F, Cook EH, Pomeroy J, Realmuto G, TanguayP: Practice parameters for the assessment and treatmentof children, adolescents, and adults with autism andother pervasive developmental disorders: AmericanAcademy of Child and Adolescent Psychiatry WorkingGroup on Quality Issues. J Am Acad Child Adolesc Psychiatry, 1999, 38, 32S-54S.
127. Whitaker-Azmitia PM: Behavioral and cellular consequences of increasing serotonergic activity during braindevelopment: A role in autism? Int J Dev Neurosci,2005, 23, 75-83.
128. Wilcox J, Tsuang MT, Ledger E, Algeo J, Schnurr T:Brain perfusion in autism varies with age. Neuropsychobiology, 2002, 46, 13-16. (Pubitemid 35002312)
129. Willemsen-Swinkels SH, Buitelaar JK, van Engeland H:The effects of chronic naltrexone treatment in youngautistic children: a double-blind placebo-controlledcrossover study. Biol Psychiatry, 1996, 39, 1023-1031. (Pubitemid 26191350)
130. World Health Association. The ICD-10 classification ofmental and behaviour disorders: diagnostic criteria forresearch. Geneva: World Health Organization, 1993.
131. Yang WH, Jing J, Xiu LJ, Cheng MH, Wang X, Bao P,Wang QX: Regional cerebral blood flow in children withautism spectrum disorders: a quantitative 99 mTc-ECDbrain SPECT study with statistical parametric mappingevaluation. Chin Med J (Engl), 2011, 124, 1362-1366.
132. Yokoyama H, Hirose M, Haginoya K, Munakata M,Iinuma K: Treatment with fluvoxamine against selfinjury and aggressive behavior in autistic children(Japanese). No To Hattatsu, 2002, 34, 249-253. (Pubitemid 34496308)
133. Zuddas A, Ledda MG, Fratta A, Muglia P, Cianchetti C:Clinical effects of clozapine on autistic disorder. AmJ Psychiatry, 1996, 153, 738. (Pubitemid 26133642)